Nursing Review Issue 3 | May-Jun 2018 | Page 29

workforce their main reason for leaving. The second most popular reason was trying something different, and that was 38 per cent. And 22 per cent said they were not paid enough. So there’s some real opportunity to have a look at those reasons for leaving and see if we can address some of those in order to retain workers. You said what emerged from HESTA’s discussions with peak bodies, unions, employers and members was a vivid picture of a dynamically changing industry. What were some of the key things you were repeatedly hearing? This issue of a dynamically changing industry was very strong from all the interviews we did. Also, societal and demographic changes. For example, the fact that dementia care is now core business in this area. The ‘Uber-isation’ of care was mentioned a lot, with more consumer directed care, having greater choice as consumers, and new care models and new skills. Both employees and employers put forward a range of suggestions to improve retention and attract new staff. What were some that stood out to you? The things that employers are doing to retain aged care workers or attract them are very interesting. First of all, it’s clear that they are adapting their business models. I think the key area of change is switching to more service-oriented approaches and doing that to attract and retain not only clients but also employees. There was a strong focus on flexible rosters and greater certainty of hours for employees. This is something we heard from employees as well as employers. Also, if we’re going to address this tremendous need to have a growing workforce, there is an opportunity to look at retention of experienced, older employees. How do we support workers to stay in the industry? When we asked employees why they would stay in the industry, the key themes were better working conditions and greater employee recognition. They felt that would make a big difference to their job satisfaction and engagement. Also, employees said they want more time to care for their clients, and they want to cut through some of the red tape that surrounds their roles. What do you hope people will take away from this report? The key aspect is the incredible opportunity in the aged care sector. This industry is on the cusp of significant change, and there is such an opportunity for both employers and employees in the sector. It’s an exciting time to be involved in this industry, but I also think it will be a challenge to be proactive and thoughtful in how we attract and retain employees. If, as a country, we are going to look after our elders in a sustainable way and deliver high-quality service, we need to focus on the workforce, on giving them the recognition they’re looking for, on addressing their working conditions, and on cutting some of the red tape. The organisations that will do very well in the future will be those that focus on these challenges. That’s the key takeout we hope people will see in the report.  ■ 1 PBS Information: This product is listed on the National Immunisation Programme (NIP) for children only and is not listed on the PBS. Refer to the NIP Schedule. Please review full Product Information before prescribing. Product Information is available on request on 1800 675 229 or at www.pfizer.com.au Indications: Active immunisation for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults and children from 6 weeks of age. Dose: 0.5 mL I.M. Infants 6 weeks to 6 months of age: 3 doses at least one month apart. A single booster should be given in the second year, at least 2 months after the primary series. Previously unvaccinated children: Varies with age at first dose, see full PI. Children previously vaccinated with Prevenar (7vPCV): Children 12 months to 5 years who have completed primary infant immunisation with 7vPCV and children 6 to 17 years who have received one or more doses of 7vPCV may receive 1 dose, at least 8 weeks after the final dose of 7vPCV. Adults: 1 dose. Special Populations (higher risk, e.g. HIV, SCD): 1 dose. HSCT: 4 doses. If sequential administration of Prevenar 13 and 23vPPV is considered, give Prevenar 13 first. Contraindications: Hypersensitivity to any component of the vaccine, including diphtheria toxoid. Allergic or anaphylactic reaction following prior administration of 7vPCV. Precautions: Do not administer intravenously, intravascularly, intradermally or subcutaneously. Avoid injecting into or near nerves or blood vessels. Do not inject into gluteal area. Postpone administration in acute, moderate or severe febrile illness. Only protects against Streptococcus pneumoniae serotypes included in the vaccine and may not protect all individuals from pneumococcal disease. Consider the risks of I.M injection in infants or children with thrombocytopenia or any coagulation disorder. Appropriate treatment and supervision must be readily available in case of a rare anaphylactic event. Prophylactic antipyretic medication is recommended for children receiving concomitant whole-cell pertussis vaccines, and for children with seizure disorders or history of febrile seizures. Consider the potential risk of apnoea when administering to very premature infants. Very Common/Common Adverse Effects: Children 6 weeks to 5 years: Injection site reactions (redness, pain, swelling), fever, diarrhoea, vomiting, decreased appetite, drowsiness/increased sleep; restless sleep/decreased sleep, rash, irritability. Children and adolescents 5 to 17 years: Irritability, Injection site reactions (redness, pain, swelling), somnolence, poor quality sleep, injection site tenderness (including impaired movement), fever, decreased appetite, vomiting, diarrhoea, headaches, rash. Adults: Diarrhoea, vomiting, nausea, chills, fatigue, injection site reactions (redness, pain, swelling), limitation of arm movement, fever, new or aggravated joint or muscle pain, decreased appetite, headaches, rash. Adults >65 years reported fewer adverse effects than younger adults. Adverse effects were generall y most common in young adults 18 to 29 years. See full PI for details (V10516). References: 1. PREVENAR 13 ® Approved Product Information. ®Registered trademark. Pfizer Australia PTY Ltd. Sydney, Australia. PP-PNA-AUS-0060. S&H 05/18 PFPFSH0138/NRHPA nursingreview.com.au | 27